IDEXX Laboratories (IDXX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Annual meeting scheduled for May 12, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by May 11, 2026.
Voting matters and shareholder proposals
Election of three directors: Daniel M. Junius, Lawrence D. Kingsley, and Sophie V. Vandebroek, PhD.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the current fiscal year.
Advisory vote on executive compensation (say-on-pay) is recommended for approval.
Proposal to amend the certificate of incorporation to declassify the board is recommended for approval.
Proposal to allow shareholders owning 25% of shares to call a special meeting is recommended for approval.
Shareholder proposal to give shareholders the ability to call a special meeting is recommended against.
Board of directors and corporate governance
Board recommends all director nominees for election.
Board supports declassification to move toward annual director elections.
Latest events from IDEXX Laboratories
- 2025 saw robust growth, innovation, and governance changes, with key shareholder votes ahead.IDXX
Proxy filing27 Mar 2026 - 2025 saw robust growth, innovation, and governance changes, with key shareholder votes ahead.IDXX
Proxy Filing13 Mar 2026 - Innovation and global expansion drive double-digit growth and new diagnostic adoption.IDXX
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Strong innovation-led growth and margin expansion expected to continue into 2026.IDXX
BofA Securities Animal Health Summit26 Feb 2026 - Double-digit revenue and EPS growth in 2025, with strong 2026 outlook and innovation momentum.IDXX
Q4 20253 Feb 2026 - Q2 revenue up 6%–7%, but EPS down 9% on litigation; gross margin rises to 61.7%.IDXX
Q2 20242 Feb 2026 - Double-digit growth driven by innovation, new diagnostics, and global expansion.IDXX
Investor Day 20242 Feb 2026 - Innovation and margin expansion drive growth despite vet visit headwinds.IDXX
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 7% to $976M, EPS $2.80, guidance trimmed amid U.S. headwinds, $89M litigation accrual.IDXX
Q3 202417 Jan 2026